Skip to main content

Table 1 In vitro antimicrobial susceptibility of ESBL producing and ESBL non-producing P. mirabilis isolates

From: The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea

Antimicrobial agent

No. (%) of susceptible isolate

p value

non-ESBL-producing group N = 48

ESBL producing groupN = 14

Ampicillin

26 (54.2)

1 (7.1)

0.002

Ampicillin/sulbactam

37 (77.1)

4 (28.6)

0.003

Piperacillin/tazobactam

47 (97.9)

12 (100)

0.617

Aztreonam

45 (95.7)

8 (61.5)

0.004

Cefoxitin

42 (87.5)

5 (41.7)

0.002

Cefotaxim

43 (89.6)

3 (23.1)

<0.001

Ceftazidime

46 (95.8)

10 (71.4)

0.02

Cefepime

46 (95.8)

4 (28.6)

<0.001

Meropenem

44 (91.7)

14 (100)

0.297

Levofloxacin

36 (75.0)

6 (46.2)

0.088

Amikacin

47 (97.9)

11 (78.6)

0.033

Gentamicin

34 (70.8)

3 (21.4)

0.001

Trimethoprim /sulfamethoxazole

29 (60.4)

4 (30.8)

0.057+

  1. ESBL, extended spectrum β-lactamases